27925180|t|A 16 Yin Yang gene expression ratio signature for ER+ / node- breast cancer
27925180|a|Breast cancer is one of the leading causes of cancer death in women. It is a complex and heterogeneous disease with different clinical outcomes. Stratifying patients into subgroups with different outcomes could help guide clinical decision making. In this study, we used two opposing groups of genes, Yin and Yang, to develop a prognostic expression ratio signature. Using the METABRIC cohort we identified a16- gene signature capable of stratifying breast cancer patients into four risk levels with intention that low-risk patients would not undergo adjuvant systemic therapy, intermediate - low-risk patients will be treated with hormonal therapy only, and intermediate -high- and high-risk groups will be treated by chemotherapy in addition to the hormonal therapy. The 16- gene signature for four risk level stratifications of breast cancer patients has been validated using 14 independent datasets. Notably, the low-risk group (n = 51) of 205 estrogen receptor-positive and node negative (ER+ / node-) patients from three different datasets who had not had any systemic adjuvant therapy had 100% 15- year disease-specific survival rate. The Concordance Index of YMR for ER+ / node negative patients is close to the commercially available signatures. However, YMR showed more significance (HR = 3.7, p = 8.7e-12) in stratifying ER+ / node- subgroup than OncotypeDx (HR = 2.7, p = 1.3e-7), MammaPrint (HR = 2.5, p = 5.8e-7), rorS (HR = 2.4, p = 1.4e-6), and NPI (HR = 2.6, p = 1.2e-6). YMR signature may be developed as a clinical tool to select a subgroup of low-risk ER+ / node- patients who do not require any adjuvant hormonal therapy (AHT).
27925180	5	13	Yin Yang	T017	UMLS:C0017337
27925180	14	29	gene expression	T038	UMLS:C0017262
27925180	50	53	ER+	T038	UMLS:C2938924
27925180	56	75	node- breast cancer	T038	UMLS:C3160889
27925180	76	89	Breast cancer	T038	UMLS:C0006142
27925180	122	128	cancer	T038	UMLS:C0006826
27925180	129	134	death	T038	UMLS:C0011065
27925180	138	143	women	T098	UMLS:C0043210
27925180	179	186	disease	T038	UMLS:C0012634
27925180	247	256	subgroups	T170	UMLS:C1515021
27925180	298	322	clinical decision making	T058	UMLS:C4042877
27925180	332	337	study	T062	UMLS:C0008972
27925180	370	375	genes	T017	UMLS:C0017337
27925180	377	389	Yin and Yang	T017	UMLS:C0017337
27925180	404	414	prognostic	T201	UMLS:C1511294
27925180	415	425	expression	T038	UMLS:C0017262
27925180	453	461	METABRIC	T170	UMLS:C0242356
27925180	462	468	cohort	T062	UMLS:C0086027
27925180	526	539	breast cancer	T038	UMLS:C0006142
27925180	636	652	systemic therapy	T058	UMLS:C1515119
27925180	654	666	intermediate	T082	UMLS:C0205103
27925180	695	707	treated with	T058	UMLS:C0332293
27925180	708	724	hormonal therapy	T058	UMLS:C0279025
27925180	735	747	intermediate	T082	UMLS:C0205103
27925180	784	791	treated	T058	UMLS:C0332293
27925180	795	807	chemotherapy	T058	UMLS:C3665472
27925180	827	843	hormonal therapy	T058	UMLS:C0279025
27925180	888	903	stratifications	T170	UMLS:C0008902
27925180	907	920	breast cancer	T038	UMLS:C0006142
27925180	939	948	validated	T062	UMLS:C1519941
27925180	970	978	datasets	T170	UMLS:C0150098
27925180	1002	1007	group	T098	UMLS:C1257890
27925180	1024	1050	estrogen receptor-positive	T038	UMLS:C2938924
27925180	1055	1068	node negative	T038	UMLS:C3160889
27925180	1070	1073	ER+	T038	UMLS:C2938924
27925180	1076	1081	node-	T038	UMLS:C3160889
27925180	1113	1121	datasets	T170	UMLS:C0150098
27925180	1151	1167	adjuvant therapy	T058	UMLS:C0677850
27925180	1222	1239	Concordance Index	T170	UMLS:C0918012
27925180	1243	1246	YMR	T058	UMLS:C2698560
27925180	1251	1254	ER+	T038	UMLS:C2938924
27925180	1257	1270	node negative	T038	UMLS:C3160889
27925180	1296	1308	commercially	T170	UMLS:C0680536
27925180	1340	1343	YMR	T058	UMLS:C2698560
27925180	1408	1411	ER+	T038	UMLS:C2938924
27925180	1414	1419	node-	T038	UMLS:C3160889
27925180	1420	1428	subgroup	T170	UMLS:C1515021
27925180	1434	1444	OncotypeDx	T058	UMLS:C2698560
27925180	1469	1479	MammaPrint	T058	UMLS:C2827401
27925180	1504	1508	rorS	T058	UMLS:C2698560
27925180	1537	1540	NPI	T058	UMLS:C2698560
27925180	1565	1568	YMR	T058	UMLS:C2698560
27925180	1610	1614	tool	T170	UMLS:C0037589
27925180	1627	1635	subgroup	T170	UMLS:C1515021
27925180	1648	1651	ER+	T038	UMLS:C2938924
27925180	1654	1659	node-	T038	UMLS:C3160889
27925180	1701	1717	hormonal therapy	T058	UMLS:C0279025
27925180	1719	1722	AHT	T058	UMLS:C0279025